A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on the preclinical work demonstrating that bendamustine...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Clinical Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400650/
https://ncbi.nlm.nih.gov/pubmed/27655665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12054
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items